Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 30, 2004. The report primarily details changes in directors' interests in ordinary shares and provides six-monthly returns regarding various employee share option schemes and blocklisting activities for the period from June 28, 2003, to December 29, 2003 (with one scheme ending December 31, 2003).
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on equity structure and share option administration.
- Total Shares in Issue: 5,949,453,777 (as of the end of the reporting period).
- Directors' Interests: Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) hold interests in the GlaxoSmithKline Employee Trust ("GSK Trust") as potential beneficiaries.
Material Changes and Share Activity
The filing reports specific transactions related to employee share schemes and blocklisting:
- Trust Transfer: On January 27, 2004, the GSK Trust transferred 9,319 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Share Issuances (June 28 - Dec 29/31, 2003):
- Glaxo Wellcome International Share Option Scheme: 984,560 shares issued.
- SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS): 926,336 shares issued.
- Glaxo Group Limited Share Option Scheme: 694,155 shares issued.
- SmithKline Beecham 1989 Executive Share Option Plan (Approved): 267,748 shares issued.
- SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - Ordinary): 207,418 shares issued.
- GlaxoSmithKline Share Option Plan - ADS: 101,234 shares issued.
- GlaxoSmithKline Savings Related Share Option Scheme: 73,936 shares issued.
- GlaxoSmithKline Share Option Plan - Ordinary Shares: 47,999 shares issued.
- Other schemes reported minimal or zero issuances during the period.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure regarding share ownership and option scheme administration.
Investor Verification Checklist
- Verify the total number of shares in issue (5,949,453,777) against the company's latest annual report to confirm capital structure.
- Review the specific terms of the "GlaxoSmithKline Employee Trust" to understand the nature of the directors' indirect interests.
- Confirm the dilution impact of the approximately 2.9 million shares issued across various schemes during the six-month period.
- Check subsequent filings for any changes in the blocklisted share counts for the listed schemes.